Memantine Use Should Be Restricted, U.K. Cost-Effectiveness Group Says
This article was originally published in The Pink Sheet Daily
Executive Summary
National Institute for Clinical Excellence recommends against using Lundbeck’s Ebixa (Forest’s Namenda in the U.S.) for treating moderately severe to severe Alzheimer’s disease. Group also recommends against use of acetylcholinesterase inhibitors for mild to moderate Alzheimer’s.